WEE1 and neoplasm: In another combination study, while EMT6 model was largely resistant to AZD-1775, a WEE1 inhibitor currently in phase 2 clinical development [44], addition of DN052 drastically enhanced tumor growth inhibition compared to either agent alone (Fig. 4b).